Clinical evaluation reveals asciminib targets the ABL myristoyl pocket in chronic myeloid leukemia, highlighting potential safety advantages.
Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better efficacy and safety and fewer side effects than currently available frontline ATP-competitive tyrosine kinase inhibitors (TKIs).
No takes yet. Share an insight, caveat, or question.
Hochhaus et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: